Full-Time

Medical Director / Senior Medical Director

Neumora

Neumora

51-200 employees

Develops precision medicines for CNS disorders

Compensation Overview

$289.8k - $367.9k/yr

+ Discretionary year-end bonus + 401(k) match

Remote in USA

Remote

PhD, MD

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Science
Data Analysis

Get referred to Neumora

See people who can refer or advise you

Requirements
  • MD required
  • 3+ years of relevant experience as a Medical Director in the biotech or pharmaceutical industry or equivalent
  • Psychiatry drug development experience required
  • Experience in leading medical and scientific aspects of clinical studies on cross functions teams
  • Ability to critically review, analyze and interpret key aspects of clinical study conduct, including research design, methods, and outcome measures, is required
  • Ability to work in a remote environment and with distributed teams; startup experience preferred
  • Self-starter who can independently lead assigned projects
  • Demonstrated ability to engage and influence diverse stakeholders from a variety of professional backgrounds
  • Psychiatry drug development experience required, Psychogeriatric or Neurodegeneration development experience a plus
  • 3+ years of relevant experience as a Medical Director in the biotech or pharmaceutical industry or equivalent
  • Active medical license desirable
Responsibilities
  • Provides clinical development and medical leadership/oversight of clinical programs to ensure timely delivery of clinical deliverables.
  • Ensures clinical programs support patient safety and provides oversight of patient safety in clinical studies.
  • As the primary medical expert for assigned study(ies), they are the first point of contact internally and externally for questions regarding the study (e.g. eligibility, enrollment; safety and patient management). Monitors study progress to ensure proper study conduct and adherence to the protocol, leads data review, evaluation, and analyses with support from the cross functional team.
  • Takes a key role in the authoring of critical study documents (e.g., CSR, IB, protocol synopsis).
  • Contributes to the analysis and interpretation of data generated internally or externally and present study updates, interim results, and final headline data to senior management as required.
  • Provides medical input and contributes to the clinical development sections of regulatory documents such as IND, CIOMS, DSUR, Dossiers, and contributing to responses to regulatory agencies regarding questions about complex clinical development issues (e.g., safety or efficacy).
  • Contributes to the cross functional development of clinical development plans (CDPs) that integrate pre-clinical, early clinical findings and data sciences approaches - working to ensure cross-functional alignment on an ongoing basis throughout the phases of clinical development.
  • Collaborates with teams on the development of translational and precision phenotyping strategies and contributes to the design of scientifically rigorous clinical development studies and programs utilizing a data biopsy signature/precision phenotype approach. Ensures that teams appreciate the clinical relevance and applicability of the approaches considered.
  • Identifies and engages with external Key Opinion Leaders to address scientific and medical questions relevant to the program.
  • Helps identify global study sites and foster relationships with study investigators.
  • Ensures that Serious Adverse Events are properly reported.
  • Implements clinical R&D policies, SOPs, and related directives.
  • As required, supports any needed due diligence of potential in-licensing drug candidates and/or technologies and present recommendations to leadership
Desired Qualifications
  • Ph.D. and/or board certification in psychiatry preferred
  • Active medical license desirable
  • Startup experience preferred in remote environment
  • Neurodegeneration development experience a plus
  • Psychogeriatric or Neurodegeneration development experience a plus
  • Active medical license desirable

Preparing a concise company summary for Neumora Therapeutics based on provided description.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Get referred to Neumora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 15, 2026 navacaprant failure forced focus onto NMRA-511, 898, and 215.
  • July 27, 2026 NMRA-215 toxicology cleared and IND submission targets Q4 2026.
  • Neumora still guides cash runway into Q3 2027 after a 35% workforce cut.

What critics are saying

  • Navacaprant's June 2026 Phase 3 collapse destroys Neumora's lead asset and credibility.
  • NMRA-898 remains Phase 1; any late-2026 miss leaves Neumora without a clinic-ready franchise.
  • Q3 2027 cash runway is existential if NMRA-511, NMRA-898, or NMRA-215 stall.

What makes Neumora unique

  • NMRA-511's 2026 Alzheimer's agitation signal supports a differentiated V1aR precision bet.
  • NMRA-898 offers a once-daily M4 PAM schizophrenia program with 80-100-hour half-life.
  • NMRA-215 targets obesity through a brain-penetrant NLRP3 inhibitor, not another GLP-1.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Company Equity

Paid Vacation

Paid Sick Leave

Paid Holidays

Disability Insurance

Parental Leave

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

2%
Associated Press
Jun 15th, 2026
Neumora discontinues navacaprant after Phase 3 trial failures, cuts workforce by 35%

Neumora Therapeutics announced its Phase 3 KOASTAL-2 and -3 studies of navacaprant for major depressive disorder failed to achieve primary or key secondary endpoints. The company is discontinuing navacaprant development and reducing its workforce by approximately 35%, resulting in $10 million in annualised cost savings. Neumora is refocusing on its clinical portfolio, including NMRA-511 for Alzheimer's disease agitation, NMRA-898 for schizophrenia and NMRA-215 for cardiometabolic disease. The company expects to complete several studies and initiate new clinical trials by year-end 2026. Following the restructuring, which will incur approximately $2 million in one-time costs, Neumora expects its current cash to provide runway into the third quarter of 2027. The KOASTAL studies enrolled 852 patients, with navacaprant showing similar efficacy to placebo.

Yahoo Finance
Apr 6th, 2026
Neumora Therapeutics to participate in 25th annual needham virtual healthcare conference.

Neumora Therapeutics to participate in 25th annual needham virtual healthcare conference. Neumora Therapeutics, Inc.

Yahoo Finance
Mar 31st, 2026
Neumora raises $182.5M, extends cash runway to Q3 2027 despite Alzheimer's drug delays

Neumora Therapeutics has reported a cash position of $182.5 million in cash, cash equivalents and marketable securities as of 31 December 2025, expected to support operations into the third quarter of 2027. The company's net loss for 2025 was comparable to 2024. Neumora announced positive Phase Ib results for NMRA-511 in Alzheimer's disease agitation and has fully enrolled KOASTAL-2 and KOASTAL-3 studies for navacaprant, with data expected in the second quarter of 2026. The company also reported promising data for NMRA-898 in schizophrenia and class-leading weight loss results for NMRA-215. However, unexpected adverse findings in a rat toxicology study for NMRA-215 have delayed clinical trials until the first quarter of 2027.

The Manila Times
Feb 4th, 2026
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

Neumora Therapeutics to participate in Guggenheim Emerging Outlook: Biotech Summit 2026. By GlobeNewswire February 4, 2026 WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) - Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m. ET in New York, NY. A live webcast of the fireside chat will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Neumora Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical and computational tools to generate insights that can enable precision medicine approaches. Neumora's mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases. Neumora Contact: Helen Rubinstein 617-402-5700 [email protected]

BioGeneration Ventures
Jul 10th, 2025
Brenig Therapeutics Announces Appointments of David L. Lucchino as CEO and Tien Dam, M.D., as Chief Medical Officer, Expands Pipeline

Dr. Dam joins Brenig from Neumora Therapeutics, where she was Vice President of Clinical Development, leading strategy and execution across neuropsychiatry and neurodegeneration programs.